Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 386, Issue 9991, 2015, Pages 360-368

  Chapman, Kenneth R ^a   Burdon, Jonathan G W ^b   Piitulainen, Eeva ^c   Sandhaus, Robert A ^d   Seersholm, Niels ^e   Stocks, James M ^f   Stoel, Berend C ^g   Huang, Liping ^h   Yao, Zhenling ^h   Edelman, Jonathan M ^h   McElvaney, Noel G ⁱ  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b ST VINCENT S HOSPITAL   (Australia)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d DEPARTMENT OF MEDICINE   (United States)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF TEXAS AT TYLER   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h CSL BEHRING   (United States)

ⁱ BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; PLACEBO;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BACKACHE; BREAST METASTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DENSITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; INFLUENZA; INVESTIGATIVE PROCEDURES; LOBECTOMY; LOWER RESPIRATORY TRACT INFECTION; LUNG DENSITY; LUNG EMPHYSEMA; LUNG PARENCHYMA; LUNG RESECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SEPSIS; SINUSITIS; TOTAL LUNG CAPACITY; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIAL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY EMPHYSEMA; RADIOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; TOMOGRAPHY, X-RAY COMPUTED; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937969384     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60860-1     Document Type: Article

References (24)

1. CB Laurell, S Eriksson The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency Scand J Clin Lab Invest 115 1963 132 140
2. JE Gadek, GA Fells, RL Zimmerman, SI Rennard, RG Crystal Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema J Clin Invest 68 1981 889 898
3. MD Wewers, MA Casolaro, SE Sellers et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema N Engl J Med 316 1987 1055 1062
4. B Burrows A clinical trial of efficacy of antiproteolytic therapy: can it be done? Am Rev Respir Dis 127 1983 S42 S43
5. S Idell, AB Cohen Alpha-1-antitrypsin deficiency Clin Chest Med 4 1983 359 375
6. KR Chapman, RA Stockley, C Dawkins, MM Wilkes, RJ Navickis Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis COPD 6 2009 177 184
7. 1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group Eur Respir J 10 1997 2260 2263
8. M Wencker, B Fuhrmann, N Banik, N Konietzko for Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor Chest 119 2001 737 744
9. 1 decline in individuals with severe deficiency of alpha1-antitrypsin, The Alpha-1-Antitrypsin Deficiency Registry Study Group Am J Respir Crit Care Med 158 1998 49 59
10. PA Dawkins, LJ Dowson, PJ Guest, RA Stockley Predictors of mortality in alpha1-antitrypsin deficiency Thorax 58 2003 1020 1026
11. A Dirksen, JH Dijkman, F Madsen et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy Am J Respir Crit Care Med 160 1999 1468 1472
12. A Dirksen, E Piitulainen, DG Parr et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency Eur Respir J 33 2009 1345 1353
13. RA Stockley, DG Parr, E Piitulainen, J Stolk, BC Stoel, A Dirksen Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry Respir Res 11 2010 136
14. BC Stoel, H Putter, ME Bakker et al. Volume correction in computed tomography densitometry for follow-up studies on pulmonary emphysema Proc Am Thorac Soc 5 2008 919 924
15. NR Anthonisen, J Manfreda, CP Warren, ES Hershfield, GK Harding, NA Nelson Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Ann Intern Med 106 1987 196 204
16. DG Parr, A Dirksen, E Piitulainen, C Deng, M Wencker, RA Stockley Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency Respir Res 10 2009 75
17. JP de-Torres, D Blanco, AB Alcaide et al. Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra PLoS One 8 2013 e60260
18. K Molloy, CP Hersh, VB Morris et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes Am J Respir Crit Care Med 189 2014 419 427
19. M Dahl Genetic and biochemical markers of obstructive lung disease in the general population Clin Respir J 3 2009 121 122
20. N Seersholm, A Kok-Jensen Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema? Respir Med 92 1998 241 245
21. IC Sorheim, P Bakke, A Gulsvik et al. Alpha-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts Chest 138 2010 1125 1132
22. MA Campos, F Kueppers, JM Stocks et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK) COPD 10 2013 687 695
23. J Vestbo, LD Edwards, PD Scanlon et al. Changes in forced expiratory volume in 1 second over time in COPD N Engl J Med 365 2011 1184 1192
24. PM Calverley, JA Anderson, B Celli et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789